Search hospitals
>
Ontario
>
HAMILTON
Juravinski Cancer Centre
Claim this profile
HAMILTON, Ontario L8V 5C2
Global Leader in Breast Cancer
Global Leader in Prostate Cancer
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Ovarian Cancer
474 reported clinical trials
26 medical researchers
Summary
Juravinski Cancer Centre is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Breast Cancer, Prostate Cancer, Cancer, Lung Cancer, Ovarian Cancer and other specialties. Juravinski Cancer Centre is involved with conducting 474 clinical trials across 379 conditions. There are 26 research doctors associated with this hospital, such as Peter Gross, Jeffrey N. Greenspoon, Timothy J. Whelan, and Som Mukherjee, MD.
Area of expertise
Breast Cancer
Juravinski Cancer Centre has run 70 trials for Breast Cancer. Some of their research focus areas include:
Prostate Cancer
Juravinski Cancer Centre has run 62 trials for Prostate Cancer. Some of their research focus areas include:
Top PIs
Peter Gross
Hamilton Health Sciences, Juravinski Hospital
2 years of reported clinical research
Jeffrey N. Greenspoon
Juravinski Cancer Centre at Hamilton Health Sciences
7 years of reported clinical research
Timothy J. Whelan
Juravinski Cancer Centre at Hamilton Health Sciences
2 years of reported clinical research
Som Mukherjee, MD
Juravinski Cancer Centre at Hamilton Health Sciences
9 years of reported clinical research
Clinical Trials running at Juravinski Cancer Centre
Cancer
Lung Cancer
Breast Cancer
Multiple Myeloma
Prostate Cancer
Pancreatic Cancer
Melanoma
Acute Myeloid Leukemia
Non-Small Cell Lung Cancer
Brain Tumor
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting
2 awards
Phase 3
10 criteria
LY4170156
for Ovarian Cancer
This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.
Recruiting
2 awards
Phase 3
4 criteria
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting
2 awards
Phase 3
4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Juravinski Cancer Centre?
Juravinski Cancer Centre is a medical facility located in HAMILTON, Ontario. This center is recognized for care of Breast Cancer, Prostate Cancer, Cancer, Lung Cancer, Ovarian Cancer and other specialties. Juravinski Cancer Centre is involved with conducting 474 clinical trials across 379 conditions. There are 26 research doctors associated with this hospital, such as Peter Gross, Jeffrey N. Greenspoon, Timothy J. Whelan, and Som Mukherjee, MD.
Where is Juravinski Cancer Centre located?
**Directions to Juravinski Cancer Centre, Hamilton, Ontario:** - **By Car:** From Hwy 6, merge onto Hwy 403, then take the Lincoln Alexander Parkway (LINC) to Upper Wentworth Street. Exit onto Concession Street and head north; the JCC is located on the left side, a few blocks up from Upper Wentworth Street. - **By Public Transit:** Hamilton Street Railway (HSR) bus routes 23 – Upper Gage and 24 – Upper Sherman stop directly outside the JCC.
Who should I call to ask about financial aid or insurance network?
Juravinski Cancer Centre offers a Financial Assistance Policy for patients. To apply, submit an application with supporting documentation to Hamilton Medical Center’s Patient Financial Counselor. The hospital also features a Patient and Family Resource Centre, offering resources on cancer care and financial concerns.
What insurance does Juravinski Cancer Centre accept?
The Juravinski Cancer Centre, part of Hamilton Health Sciences, accepts various insurance plans, including OHIP for Ontario residents, which covers most health care services except for specific exclusions like ambulance services and cosmetic surgery. Patients from other Canadian provinces or territories are covered through reciprocal agreements. International patients and those without health coverage must pay for services received, with international patients expected to provide a deposit. Hamilton Health Sciences also accepts private insurance plans such as Aetna Health Plans, Blue Cross Blue Shield of Georgia, Cigna Healthcare PPO, and Medicare, among others.
What awards or recognition has Juravinski Cancer Centre received?
The Juravinski Hospital and Cancer Centre Foundation (JHCCF) is currently accepting applications for its 2024 Research Grants Program. In 2023, Amaris Balitsky was recognized for her research on the effects of CAR T-cell therapy on cognition. Hamilton Health Sciences' cancer care programs were also honored at the 16th annual Quality and Innovation Awards.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.